Berger TA, Manry MW, Lindsell LB, et al. - In this single-center retrospective, comparative study, experts aspired to explore whether off-label Age-Related Eye Disease Study 2 (AREDS2) supplementation prevents visual and anatomical deterioration in non-proliferative Idiopathic Macular Telangiectasia Type 2 (IMT2). They analyzed 82 IMT2 eyes treated with AREDS2 from January 1, 2013, to January 1, 2018. The study had two arms: a non-comparative arm with all AREDS2 eyes and a comparative arm (27 AREDS2 and 42 untreated eyes) with only eyes with complete follow-up data. Better/worse eye sub-analysis was conducted in the comparative study arm. According to the findings, off-label AREDS2 supplementation in non-proliferative IMT2 can prevent anatomical and visual deterioration in a subset of eyes.